FindTrial
Sign In

A prospective cohort study of PET multi-parameters based on glucose metabolism and ER expression for predicting the efficacy of palbociclib combined with fulvestrant in the treatment of recurrent and metastatic breast cancer patients with visceral metastases

A prospective cohort study of PET multi-parameters based on glucose metabolism and ER expression for predicting the efficacy of palbociclib combined with fulvestrant in the treatment of recurrent and metastatic breast cancer patients with visceral metastases

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035487
Enrollment
Unknown
Registered
2020-08-12
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:Clinical outcome
Index test:PET&#32
multiple&#32
parameters

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ER+/HER2- recurrent and metastatic breast cancer with visceral metastasis in patients with

Exclusion criteria

Exclusion criteria: her2+;prior treatment with fulvestrant or CDK4 / 6 inhibitors; poor conditions; combined with other tumors

Design outcomes

Primary

MeasureTime frame
PFS;—

Countries

China

Contacts

Public ContactYang Zhongyi

Fudan University Shanghai Cancer Center

yangzhongyi21@163.com+86 18017312922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026